Celltrion
Overview
Celltrion is a South Korean biopharmaceutical company that specializes in the research, development, manufacturing, and sale of biosimilars and innovative therapeutics. The company's portfolio covers areas like immunology, oncology, and hematology. While its primary business is biopharmaceuticals, Celltrion also engages in strategic investments in other biotech companies and has co-launched venture funds to foster growth in the healthcare sector. For example, it became the largest shareholder in Iksuda Therapeutics, a UK-based ADC developer, through direct investment and a joint fund with Mirae Asset Group.
Portfolio Companies
5
Website
celltrion.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Kaigene Inc. | Sep 2026 | Series A | Co-investor |
| BioMe Inc. | Dec 2024 | Series A | Lead |
| Basgenbio | Jun 2023 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Celltrion based?
Celltrion is headquartered in Incheon, Incheon, South Korea.
When was Celltrion founded?
Founding year information for Celltrion is not publicly available.
How many portfolio companies does Celltrion have?
Celltrion has 5 portfolio companies in Caplight's dataset.
What are some companies in Celltrion's portfolio?
Recent investments visible on Caplight include Kaigene Inc., Kaigene Inc., Kaigene Inc., BioMe Inc., Basgenbio.
What was Celltrion's most recent investment?
Celltrion's most recent investment on Caplight was in Kaigene Inc. in 2026.
What sectors does Celltrion focus on?
Celltrion focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Celltrion focus on?
Celltrion typically invests at the Early stage.